

PROBIOTICS: RECENT ADVANCES AND FUTURE PROSPECTS

Archana Yadav¹, Harish Chandra^{2*} and Vineet Kumar Maurya³¹Department of Microbiology, Institute of Biosciences and Biotechnology, C.S.J.M. University, Kanpur- 208 024, Uttar Pradesh, India.²High Altitude Plant Physiology Research Centre, ³Department of Botany and Microbiology, H. N. B. Garhwal University (A Central University), Srinagar, Garhwal-246174, Uttarakhand, India
Email: hreesh5@gmail.com

Received-24.09.2017, Revised-22.11.2017

Abstract: Probiotics are the microorganism which imparts beneficial effect in the human body. The consumption of probiotic in the form of powder, capsule and drinks restore the beneficial microflora in gut and in turn help the human being by enhancing immune system. The present review focusing on the role of probiotics for its possible role in controlling and treating diseases such as urinary tract infection, diarrheal disease caused by bacteria, oral infection i.e. gingivitis, oral cavity and cancer. This review also focuses on regulation, side effect, safety and future prospects of probiotics.

Keyword: Probiotics, UTI, Oral hygiene, Diarrhea

INTRODUCTION

Increasing resistant of the microbes against the multiple antibiotics has led a great threat to human health. The researchers all over the world are looking for the alternate source. One way to prevent disease is to use third generation antibiotics to control microbes while the other way is to use beneficial or antagonistic microbes that act on disease causing microbe by competition for space and nutrition. Microbe used for control of microorganism should be harmless to the host and does not have any effect on the natural biome of human gut. This method will be better in terms of side effects as in case of chemotherapy. The term 'probiotics' are combination of two word (pro-for and biotics- life). Probiotics is a mechanism that employs culture suspension of microbes for removing the pathogens from body and maintaining milieu *interior* of body. Probiotics plays significant role for various organs and systems of the body like it has great impact on gastrointestinal tract,

cancer, vaginal infections, allergies, respiratory diseases etc.

The use of antibiotic was started after its discovery by Alexander Fleming in 1928. The discovery of antibiotic increased the life expectancy of human beings and also useful substance to control the sepsis after post-operation. Before the discovery of antibiotic and antiseptic agent the death of most of female occurs after delivery and during delivery. Now due to increase used of antibiotic and disinfectant the post operative infection has been largely controlled. The large population of the world directly or indirectly expose to antibiotics. The disadvantage of antibiotics is its side effect which includes liver damage, gastro intestinal disturbance, temporary or permanent deafness, nephrotoxicity, nausea, allergic reaction etc. (Table 1) and another problem associated with antibiotic is that it does not differentiate between beneficial and harmful microorganism and result in disturbing normal microflora which in turn cause deficiency of vitamins such as Vitamin B, Vitamin K etc. in human body.

Table 1. Antibiotic and its mechanism of action and their side effects.

| S.No | Antibiotic | Mechanism of Action | Side effects | Reference |
|------|--|---|---|---|
| 1 | Metronidazole | disrupts DNA of microbial cells by preventing nucleic acid synthesis | Sensory neuropathy, Gastrointestinal disturbance, neoplasia | Zivkovic et al. (2001); Friedman et al. (2009), |
| 2 | Penicillin | Interfere with enzymes required for the synthesis of the peptidoglycan layer. | Skin Allergies | Bhattacharya (2010) |
| 3. | Clindamycin | Inhibit protein synthesis by interfering with the transpeptidation reaction, | Anaphylaxis, Leucopenia, Hepatotoxic | Granowitz and Brown (2008) |
| 4 | Aminoglycoside (streptomycin, kanamycin, neomycin, gentamicin, tobramycin, and amikacin) | Inhibit protein synthesis by inhibiting 30S ribosomal subunit | Ototoxic effect Nephrotoxic | Forge and Schacht (2000) |
| 5 | Chloramphenicol | Inhibit bacterial growth by binding to the 50S ribosomal | Aplastic anaemia | Cruchaud et al. (1963) |

*Corresponding Author

| | | | | |
|----|------------------|---|--|---------------------------|
| | | subunit and inhibiting protein synthesis in prokaryotes | | |
| 6 | Tetracycline | Inhibit protein synthesis by blocking the binding of the aminoacyl-tRNA to the acceptor site on the mRNA-ribosome complex | Yellowing of teeth | Sánchez et al. (2004) |
| 7 | Sulfonamide | Antagonist, inhibition of metabolic pathway | Dermonecrotic, Stevens-Johnson syndrome | Roujeau et al. (1995) |
| 8 | Amoxicillin | Inhibition of cell wall synthesis of bacteria | Diarrhoea, Sore in mouth, fever, swollen gland, reversible leucopenia Allergic skin reactions | Paavonen et al. (1989) |
| 9 | Fluoroquinolones | Prevent replication, transcription, and repair of bacterial DNA by inhibiting DNA gyrase enzyme | Retinopathies, chondrotoxic effects | 1. Barnhill et al. (2012) |
| 10 | Vancomycin | inhibit cell wall synthesis of Gram-positive bacteria by binding C-terminal acyl-D-alanyl-D-alanine (acyl-D-Ala-D-Ala) containing residues in peptidoglycan precursors. | Vancomycin can produce pseudoallergic reactions. Rapid intravenous infusion may trigger histamine release, which causes a variety of symptoms, including erythematous or urticarial reactions, flushing, tachycardia, and hypotension. The extreme flushing is called redman syndrome. The most significant untoward reactions are ototoxicity and nephrotoxicity. | Daniel (2013) |
| 11 | Linezolid | inhibiting the initiation process of protein synthesis | cause anemia by suppressing erythropoiesis and thrombocytopenia. | Bernstein et al.(2003) |

In past few years India had witnessed the increased faith towards the traditional system of medicine. In India Ayurveda was practiced since time immemorial and people are getting good result however this system has slow acting effect on human body.

The present chapter focuses on the beneficial effect of Probiotics in various ailments that can be controlled and treated by taking consortium of beneficial bacterial species which can be easily adapted and tolerate the gut environment of human being and impart health benefits. As per FAO/ World Health Organization (2001), probiotics are mixture of living microorganism which imparts health benefits when administrated in adequate amount. The history of Probiotics dates back when Elie Metchnikoff gave the concept of Probiotics and discovered the process of phagocytosis in which he emphasized the role of macrophage and microphage that play important role in prevention of infection. For this contribution Elie Metchnikoff was awarded Nobel Prize in 1908. Elie Metchnikoff observed that consumption of useful microorganism (presently known as Probiotics) would modify the gut flora and harmful microorganism will be replaced by the useful bacteria. The fermentative process of bacteria produce lactic acid which inhibit the growth of proteolytic bacteria lowering down the pH of gut which in result inhibit the growth of harmful bacterial species. Indian literature there is well documented that consumption of yoghurt is good for health and longevity. Elie Metchnikoff also observed that Russian and Bulgarians consumed fermented milk in their diets were exceptionally long lived. Based on these observations Metchnikoff proposed

that consumption of fermented milk would repopulate the intestine with harmless lactic-acid bacteria

Most probiotics are bacteria similar to those naturally found in people's guts, especially in those of breastfed infants (who have natural protection against many diseases). Most often, the bacteria come from two groups, *Lactobacillus* or *Bifidobacterium*. Within each group, there are different species (for example, *Lactobacillus acidophilus* and *Bifidobacterium bifidus*), and within each species, different strains (or varieties). A few common probiotics, such as *Saccharomyces boulardii*, are yeasts, which are different from bacteria. Commercially available probiotic based products in the market are yoghurt, ice creams milk beverages, capsules, antibiotic supplemented with Probiotics, tablet, powder etc. *Lactobacillus* and *Bifidobacterium* genera, which are found naturally in dairy products, are commonly used strains for preparation of Probiotics.

Probiotics against diarrheal disease

Indian subcontinent is very prone to diarrheal disease because of poor quality or inadequate drinking water and poor sanitation. Most of the people residing in rural areas still do not have access to clean water. The source of water for drinking is tube well, hand pump and traditional well. So, occurrence and prevalence of gastrointestinal problem is quiet common in villages and some urban areas. However, common types of diarrhea can be subside naturally, but bacterial associated disease such as *Salmonella* Typhi, *Shigella* sp., *Vibrio* sp. required medical attention.




Fig: Gastrointestinal tract and microorganism associated with it (Adapted from Chandra *et al.* 2016)

The microflora of new born is influenced by the mode of delivery in case of vaginal route the upper GI tract is colonized by vaginal and faecal microbiota of mother. The infant born with caesarean procedure are exposed to the microbiota of mother. The duration to establish the primary intestinal microflora vaginal delivery require only one month while caesarean require up to 6 month after birth. The initial bacterial count is unstable during first week after that the bacterial counts are found in the range $10^9 - 10^{10}$ per gram of faeces (Palmer *et al.*, 2007). The microbial flora also influence by the feeding type i.e. mother milk (Breast feeding) and formula milk feeding. In case of breast feeding microbial flora is dominated by *Bifidobacteria* and *Lactobacilli* while in formula milk feeding infant the microflora is dominated by high number of *Enterobacteriaceae*, *Bifidobacteria*, *Bacteroides*, *Clostridia* and *Enterococci*. The microflora in both cases becomes similar after infants start eating the solid foods.

In case of bacterial associated diarrhea there is administration of broad spectrum antibiotic. Several

reports published which support that Probiotics are effective in treatment and prevention of diarrhea caused by *Salmonella*. The possible mechanism suggested for prevention of diarrhea is probiotics that it causes the stabilization of the gut mucosal barrier, increasing the secretion of mucus, improving gut motility and it does not allow invading bacterial pathogen to colonise the gut and competing for the nutrient. It also produce bacteriocins (Low molecular weight antimicrobial substance) which has property to inhibit the growth of other microorganism. molecular weight antimicrobial substances (bacteriocins). It also has the ability to enhance phagocytic activity of macrophages, initiate Natural Killer cell activity, immunomodulatory activity to prevent infection (O'Hara *et al.*, 2006; Gobbato *et al.*, 2008).

L. plantarum, *L. rhamnosus*, *L. acidophilus*, *L. kefir*, *L. casei*, *St. thermophilus*, *L. delbrueckii* ssp *bulgaricus* *L. gasseri* F71, *L. gasseri* L1, *L. paracasei*, *E. faecium* are few examples of bacterial species which is responsible for preventing and controlling the diarrheal disease.




Fig. Probiotics and their possible mechanism of action

In most of the developing countries there was reported cases of Traveller diarrhea which is result of travelling to the countries where *Entamoeba histolytica* is endemic. This protozoan is the second most common causal agent of diarrhea in developing countries. This protozoan parasite is often known to coexist as a part of the normal gut microbiota. Infection due to this parasite causes diarrhea with blood and may infect other organ if not treated in time. The treatment with metronidazole and tinidazole, used to *E. histolytica* infections. However, these drugs have adverse side effect. Due to potential side effect of antibiotics researchers are now searching for alternate treatment. Sarjapuram et al (2016) investigated the effect of probiotics on the growth of Entamoeba. Their effect on *E. histolytica* growth was evaluated. *Lactobacillus casei* and *Enterococcus faecium* showed a significant reduction of up to 71%. Higher reduction was observed when tested in combination. Decreased duration of bloody diarrhea was observed when Probiotic strain of *Saccharomyces boulardii* when administered together with metronidazole in case children infected with *E. histolytica* (Dinleyici et al., 2009).

Probiotics for Urinary tract infection

Urinary tract infection is commonest disease in female as compared to male. It affects urinary bladder, ureter, genital organ and kidney. Frequently

encountered microorganisms in case of UTI are *E.coli* followed by *Staphylococcus aureus*, *Klebsiella* sp., *Enterococcus* and *Candida albicans*. The reason of higher female susceptibility to urinary tract infections in females is a result of a variety of factors, such as the close proximity of the female urethral meatus to the anus (Lipsky, 1990) short urethra and incomplete and in coordinate voiding of urine in school girls which is often leads to infection of the urinary tract (Mond et al., 1970). UTI in most cases restricted to the infection in bladder (essentially in females) with only superficial mucosal involvement, or occasionally in organ like kidneys in both genders, and in prostate in males. The incidence of UTI is higher among females as compare to males and children (Hootan, 2001 and Foxman et al., 2001). Women are more susceptible to UTI because their urethra is short, allowing quick access of bacteria to the bladder. Also a woman's urethral opening is near sources of bacteria from the anus. The incidence increases with age and sexual activity (Castellsagué et al., 2005). Rates of infection are high in postmenopausal women, because of bladder or uterine prolapse causing incomplete bladder emptying; loss of estrogen with attendant changes in vaginal flora, loss of *Lactobacilli* sp., which allows perirethral colonization with gram negative aerobes, such as *E. coli* (Pabich et al., 2003; Hu et. al., 2004

and Foxman, 2007). Catheterization is also associated with a very high incidence of UTI (Hazelett *et al.*, 2006).

Reduction of UTI cases were reduced after the administration of using vaginal route *Lactobacillus rhamnosus* GR1 in combination with either *L. reuteri* B 54 or RC 14. In this study 52 woman who had history of reoccurrence of UTI were under single weekly dose of vaginal suppositories of *Lactobacillus rhamnosus* GR1/ *L. reuteri* B 54. The result showed the reduction of UTI reoccurrence (Reid *et al.*, 1995).

In woman during gestation period susceptibility to UTI or bacterial vaginosis is greater as compared to normal woman. The using intravaginal applications of yogurt to treat woman with bacterial vaginosis in the first trimester of pregnancy reduced the risk of preterm birth or miscarriage was report by Neri *et al.* (1993). The maintenance of vaginal pH and prevalence of *Lactobacillus* spp. in vaginal region was essential for preventing bacterial vaginosis. The possible mechanism of Probiotics include it prevent the adhesion of uropathogens to the epithelial cells, some Probiotics produce hydrogen peroxide which kill the uropathogens, degradation of lipid, stimulation of secretory antibodies IgA and production of conjugated linoleic acid (Shalev, 2002). *Lactobacillus reuteri*, originally derived from mother's milk, has been reported to survive the harsh stomach environment and maintain a healthy balance of friendly bacteria in the digestive tract.

Probiotics for oral hygiene

Microorganisms present in oral cavity are considered as oral microflora. Oral cavity consists of different habitats such as teeth, tongue, gingival sulcus, cheek, soft and hard palate, tonsils. These region are colonized by bacterial species which does not cause any disease, they are normal inhabitant of oral cavity. The predominant microflora of oral cavity includes *Bacteroidetes*, *Chlamydiae*, *Firmicutes*, *Chloroflexi*, *Euryarchaeota*, *Fusobacteria*, *Proteobacteria*, *Spirochaetes*, *Synergistes* and *Tenericutes* etc (Dewhirst *et al.*, 2010). Taking Probiotics such as *L. rhamnosus* GG, *L. reuteri* and *Bifidobacterium* reported to have inhibitory action on the growth of *Streptococcus mutans* (Näse *et al.*, 2001; Nikawa *et al.*, 2004; Cildir *et al.*, 2009).

An experimental study on the effect of cheese containing *L. rhamnosus* strains GG and LC705 and *Propionibacterium freudenreichii* ssp. *shermanii* JS on *Candida* spp. responsible for oral candidiasis in case of elderly persons. After 16 weeks the number of yeast count decreased but no change in mucosal lesion was observed (Hatakka *et al.*, 2007).

The use of Probiotics enhancing the growth and number of normal micro flora of oral which inturns preventing the colonization of true pathogens, and thus, preventing the microbiological shifts associated with gingival inflammation. Kragan in 1954 done the first study on the effect of *lactobacillus* for the

treatment of inflammatory affections of the oral mucosa.

Reduced gingivitis index and plaque index was noticed after the administration of two different *L. reuteri* formulations (LR-1 or LR-2) at a dose of 2 x 10⁸ CFU per day (Krasse *et al.*, 2006). Iniesta *et al.* (2012) investigated the effect of oral Probiotics on the oral microbiota in which they administered tablets of *L. reuteri* to 40 gingivitis subjects. The effect of *L. reuteri* administered in tablets resulted in a reduction in the number of selected periodontal pathogens in the subgingival microbiota, without an associated clinical impact. Reduction in the number of oral microflora *Streptococcus mutans* and total bacteria after oral administration of fermented fermented milk containing *L. rhamnosus* SD11 or *L. bulgaricus*, once daily for 4 wk in 43 healthy young adults. The result showed the significant reductions in and total bacteria and streptococci mutans were in the probiotic group compared with the control group, and the number of lactobacilli was significantly increased in both groups after receiving fermented milks *Lactobacillus rhamnosus* SD11 (Rungsri *et al.*, 2017)

Probiotics for prevention of cancer (Anticancer properties)

Cancer is disease which can occur in any stage of life. However this condition is very rare earlier but now it became very common and number of patient increase day by day. The increased incidence was due to lack of physical work or sedentary life style, food habit and genetic makeup and radiation exposure from the environment. The treatment of cancer in modern medicine is administration of chemotherapy which had so many side effect and painful procedure. The common side effect encountered by cancer patient are fatigue, muscle pain, headache, abdominal pain, peripheral neuropathy, suppression of bone marrow which result in low count of RBCs and WBCs, thrombocytopenia (Low platelet counts), loss of hairs, weakness, loss of appetite etc. So, there is immense need of therapy which is effective and less painful to cancer patients. Some side effects are temporary and some are permanent affecting lungs, heart, kidney and other organs. In search of alternate treatment researchers have evaluated some probiotic strains for evaluation of its antitumor potential.

Effect of two probiotic strains i.e. *Lactobacillus rhamnosus* supernatant (LRS) and *lactobacillus crispatus* supernatant (LCS) on the human cervical and colon adenocarcinoma cell lines (HeLa and HT-29, respectively) was studied and found that *Lactobacillus rhamnosus* supernatant and *lactobacillus crispatus* supernatant are effective on HeLa cell lines while only the effect of *L. rhamnosus* supernatant is significant on HT-29 (Nouri *et al.*, 2016). Antitumor activity of *L. plantarum* A and *L. rhamnosus* b was evaluated by pre-inoculating mice with lactobacilli for 14 days and

then subcutaneous and orthotopic intestinal tumours were generated by pre-inoculated mice using CT26 murine adenocarcinoma cells. The oral administration with *L. plantarum* inhibited CT26 cell growth in BALB/c mice and prolonged the survival time of tumour-bearing mice (Hu *et al.*, 2015).

It is commonly known that persistent infection of human papillomavirus (HPV) is responsible for the development of cervical cancer. In one study in which 54 women that administrated the daily probiotic drink for 6 months enhanced the clearance of HPV and cervical cancer precursors (Verhoeven *et al.*, 2013). Nami *et al.* (2014), studied the effect of *L. acidophilus* 36YL strain isolated from isolated from the vagina of healthy and fertile Iranian women on four human cancer cell lines (AGS, HeLa, MCF-7, and HT-29) and one normal cell line (HUVEC) and found that the isolated strain have anticancer effects on the four tested cancer cell lines and negligible side effects on the HUVEC normal cell line

Regulation of Probiotics

Probiotics are generally used for the health supplement or preventive therapy and its status is not clearly understood by the health industry. Now a day the probiotics are gaining popularity and their demand is increasing day by day in India as well as abroad. Manufacturer are now producing probiotics and also trying to develop a new combination of Probiotics for the health benefits of people but as far as regulation is concerned these companies have shown ignorance towards regulations laid down by the respective countries. Reported published from the different countries suggested that the manufacturing companies do not follow the quality standard as written on the products. The lower count of *Bifidobacterium bifidum* in three commercial yogurts were reported in South Africa (Lourens-Hattingh and Viljoen, 2002). Temmerman *et al.* (2003) found that of isolates from 55 European probiotic products, 47% of food supplements and 40% of dairy products were mislabelled. The food supplements yielded either no viable bacteria (37%) or significantly lower counts than the dairy products, contradicting the concept that health benefits derive from the presence of a minimum concentration of live probiotic bacteria.

In India, currently, food and drugs are regulated by Prevention of Food Adulteration Act (PFA) and FDA, respectively. The Food Safety and Standards Act of 2005 (FSSA) defines the foods for special dietary uses or functional foods, nutraceuticals or health supplements. Currently in India, probiotics are characterized as functional food rather than as pharmaceutical drugs and are regulated by food laws that regulate general food items. FSSA was passed by the Indian government with the purpose to regulate different varieties of eatables regulations covering nutraceuticals, foods and dietary supplements. According to FSSA, functional foods are defined legally but categorization of food

categories, such as nutraceuticals, biotherapeutic agent is still unclear (Arora and Baldi, 2015).

Due to increasing demand of probiotics in these days, there may be the possibility of circulation of false, inferior and ineffective probiotics based products. Till 2011 there is no regulatory guideline has been developed to monitor the quality of Probiotics and Probiotic based products. So, it is very necessary to have regulatory bodies to monitor or regulate the standard of probiotic products. In other countries such as USA, European countries. Regulations on Probiotics were come into the existence in most of the developed countries. So, Indian council of Medical Research had constituted a task force in which different scientist or experts were considered for making draft guideline for standardization and evaluation of Probiotics.

ICMR-DBT guideline for Probiotics was drafted in 2011 for the evaluation and standardization of Probiotics and probiotic based products in food (Ganguly *et al.*, 2011). The salient features of ICMR-DBT are as follows:-

- ❖ Definition of Probiotics are same as laid down by the FAO/WHO, 2002
- ❖ Standardized method should be used to validate the genotypic and phenotypic identification of strain used for probiotic preparation by using modern molecular biological techniques such as 16SrRNA sequencing, DNA fingerprinting, Pulse Field Gel Electrophoresis) and PCR based techniques. Nomenclature of bacterial should be as per the ICPS (International Committee on Systematics of Prokaryotes)
- ❖ The strain used for probiotic preparation should have properties i.e. bile tolerant, gastric acid tolerant, show antimicrobial activity against pathogenic bacteria, reduce pathogen adhesion,
- ❖ Toxicity test of probiotic strain for acute, subacute and chronic toxicity if probiotic is taken in excessive amount. Before using for human being it must be tested on animal model to analyse its effect.
- ❖ Effect of probiotic on human body should be statistically and clinically proven.
- ❖ Minimal effective dose and number viable cell in cfu/ml/day should be clearly mentioned on the product.
- ❖ The product should be labeled with bacterial genus, species strain name as per the international nomenclature, evidence of health claim should be clearly mentioned, Serving quantity and storage condition must be written on the product.
- ❖ Guideline of good manufacturing process should be followed as per the HACCP (Hazard Analysis and Critical Control Point) and Codex general principle of Food Hygiene

Side Effects and Risks

Probiotics are considered safe for human uses but there is less scientific studies has been done for

safety and side effect of long term use of Probiotics. The healthy individuals have a good immune system but those people who have weakened immune system if Probiotics are given to immunocompromised patient then it may cause any health issues. *Lactobacillus* species have low pathogenicity and rarely cause any disease in human beings. However, in case immunocompromised person such as human immunodeficiency virus (HIV) infection or those who have undergone organ transplantation may get the disease from probiotics strains.

Rautio *et al.* (1999), reported the case of a 74 year old woman having hypertension and diabetes mellitus developed a liver abscess in association with pneumonia and pleural empyema. The reason traced for the infection source was found that lady has taken probiotic milk containing *L. rhamnosus* GG and a strain indistinguishable from that was isolated from the abscess. Another case reported by Mackay (1999) in which a 67 year old man developed endocarditis after dental extractions. The blood cultures studies revealed the presence of a strain of *L. rhamnosus* indistinguishable from that in probiotic capsules he had taken.

Wolf *et al.* (1998) reported no side effect or safety problem with the administration of probiotic strain *Lactobacillus reuteri* in a double-blind, placebo-controlled study in HIV adults. In search of new novel strain which can be exploited for Probiotics are an important area of research in these day however, the problem associated with the new strain is whether it is safe for food use, strain isolated from human or animal or it is genetically modified. Rungsri *et al.* (2017) done a randomised clinical trial of Probiotics (fermented milk containing *Lactobacillus rhamnosus* SD11) on 43 healthy volunteer young adults and reported no side effect after the consumption of probiotics up to 8 weeks of study period. The study stated above by different investigator suggested that more studies are required for side effect or safety problem of consuming Probiotics is required.

Future perspectives of Probiotics research

Increasing resistance in microorganism towards antibiotic is the big challenge to scientific community and till date, no method has been developed to revert back the antibiotic resistance. So, probiotic had given some hope to the community to prevent and treat gastrointestinal infection, antibiotic-associated diarrhea, urinary tract infection, ulcerative colitis, oral gingivitis and some types of cancer. Use of probiotic in India is not a new science but our ancestors using the Probiotics in the form of yogurts from the time since immemorial and getting benefits from this. Different types of probiotics are now commercialized for the use of human beings and they are in great demand among the peoples of India and abroad. The manufacturing companies claiming the beneficiary effect of their products to various ailments. The regulatory bodies which are functional in India should or must analyzed the product for the

claim that has been made by the manufacturer. As stated in above section about safety, whether the manufacturer had followed the safety measures so, that it could not produce any kind of adverse effect on the body of consumer. The use of probiotic is not limited only to the use of patient but it should be easily taken and used by healthy persons or young ones. The different consortium of different probiotic strains are used for the prevention of urinary tract infection, different types of diarrhea, cancer, ulcerative colitis, irritable bowel syndrome, lactose intolerance, pancreatitis, peptic ulcer caused by *Helicobacter pylori*, pouchitis etc.

ACKNOWLEDGEMENT

Authors are thankful to the Director, High Altitude Plant Physiology research Centre, H. N. B. Garhwal University, Srinagar, Garhwal, Uttarakhand, India for their kind support.

REFERENCES

Arora, M. and Baldi, A. (2015). Regulatory categories of Probiotics across the globe: A review representing existing and recommended categorization. Indian J Med Microbiol.33 S1:2-10

Barnhill, A.E., Brewer, M.T. and Carlson, S.A. (2012). Adverse Effects of Antimicrobials via Predictable or Idiosyncratic Inhibition of Host Mitochondrial Components. Antimicrob Agents Chem 56 (8): 4046-4051.

Bernstein, W.B., Trotta, R.F., Rector, J.T., Tiaden, J.A. and Barile, A.J. (2003). Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacotherapy 37:517-520.

Bhattacharya, S. (2010). The fact about penicillin allergy: A review. J Adv Pharma Tech Res 1(1): 11-17.

Castellsagué, X., Peeling, R.W., Franceschi, S., Sanjosé S., Smith, J.S., Albero, G., Díaz, M., Herrero, R., Muñoz, N. and Bosch, F.X. (2005). *Chlamydia trachomatis* infection in female partners of circumcised and uncircumcised adult men. Am J Epidemiol 162: 907-916.

Chandra, H., Srivastava, J. and Agarwal, R.K. (2016). Fundamental Techniques in Microbiology. John Publisher, New Delhi. ISBN 978-81-928544-1-0.

Cildir, S.K., Germec, D., Sandalli, N., Ozdemir, F.I., Arun, T., Twetman, S. and Caqlar, T. (2009). Reduction of salivary mutans streptococci in orthodontic patients during daily consumption of yoghurt containing probiotic bacteria. Eur J Orthod 31:407- 4011.

Cruchaud A., Gfeller, G., Liebeskind, B., Meykadeh, F., Choisy, R. and Hausser, E. (1963). 3 cases of blood disorders following the administration of chloramphenicol. Schweiz Med Wochenschr 93: 1471- 1475.

Daniel, E.B. (2013). Antimicrobial Drugs. *Anesth Prog* 60:111–123

Dewhirst, F.E., Chen, T., Izard, J., Paster, B.J., Tanner, A.C.R., Yu, W.H., Lakshmanan, A. and Wade, W.G. (2010). The human oral microbiome. *192* (19); 5002-5017.

Dinleyici E.C., Eren, M., Yargic, Z.A., Dogan, N. and Vandenplas, Y. (2009) Clinical efficacy of *Saccharomyces boulardii* and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amoebiasis: a prospective, randomized, open label study. *Am J Trop Med Hyg* 80(6):953–955.

FAO / WHO. (2001). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Available from. http://www.who.int/foodsafety/publications/fs_mangement/en/probiotics.pdf.

Forge, A. and Schacht, J. (2000). Aminoglycoside antibiotics. *Audiol Neurotol* 5:3–22.

Foxman, B., Somsel, P., Tallman, P., Gillespie, P., Raz, R., Colodnar, R., Kandula, D. and Sobel, J.D. (2001). Urinary Tract Infection among Women Aged 40-60 Behavioral and Sexual Risk Factors. *J Clin. Epidemiol* 54: 710-718.

Foxman, B. (2007). Urinary Tract Infection in Postmenopausal Women. *Curr Infect Dis Rep.* 1: 367-370.

Friedman, G.D., Jiang, S.F., Udaltsova, N., Quesenberry, C.P. Jr., Chan, J. and Habel, L.A. (2009) Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. *Int J Cancer* 125:2173–2178.

Ganguly, N.K., Bhattacharya, S.K., Sesikeran, B. Nair, G.B., Ramakrishna, B.S., Sachdev H.P.S., Batish, V.K.. Kanagasakiapathy, A.S., Vasantha Muthuswamy, Kathuria, S.C., . Katoch V.M, Satyanarayana, K. Toteja, G.S , Manju Rahi, Rao S. , Bhan, M.K, Kapur, R. , and Hemalatha. R. (2011). ICMR-DBT Guidelines for Evaluation of Probiotics in Food. *Indian J Med Res* 134(1): 22–25.

Gobbato, N., Maldonado Galdeano, C. and Perdigón, G. (2008). Study of some of the mechanisms involved in the prevention against *Salmonella enteritidis* serovar Typhimurium infection by lactic acid bacteria. *Food Agri Immunol* 19:11–23

Granowitz, E.V and Brown, R.B. (2008). Antibiotics adverse reaction and drug interactions. *Critical care Clinics.* 24:421-442.

Hatakka, K., Ahola A.J., Yli-Knuutila, H., Richardson, M., Poussa, T., Meurman, J.H. and Korpela, R. (2007). Probiotics reduce the prevalence of oral candida in the elderly-a randomized controlled trial. *J Dent Res* 86:125-130.

Hazelett S.E., Tsai M., Gareri M. and Allen K. (2006). The association between indwelling urinary catheter use in the elderly and urinary tract infection in the acute care. *BMC Geriatr.* 6: 15.

Hooton, T.M., Winter, C., Tiu, F. and Stamm W.E. (1995). Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. *J Am Med Assoc* 273:41-45.

Hu, J, Wang C, Ye, L., Yang, W., Huang, H., Meng, F., Shi, S, Ding, Z.(2015). Anti-tumour immune effect of oral administration of *Lactobacillus plantarum* to CT26 tumour-bearing mice. *J Biosci* 40 (2):269-79.

Hu, K.K., Boyko E.J., Scholes, D., Normand E., Chen, C.L., Grafton, J. and Fihn, S.D. (2004). Risk Factors for urinary tract infections in postmenopausal Women. *Arch. Intern. Med* 164: 989-993.

Iniesta, M., Herrera, D., Montero, E., Zurbriggen M , Matos, A.R. , Marín, M.J., Sánchez-Beltrán M.C. , Llama-Palacio, A. , Sanz, M. (2012). Probiotic effects of orally administered *Lactobacillus reuteri*-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. *J Clin Periodonto* 39(8):736-744.

Kræger, H. (1954) The treatment of inflammatory affections of the oral mucosa with a lactic acid bacteria culture preparation. *Zahnärztl Welt* 9:306–308.

Krasse, P., Carlsson, B., Dahl, C., Paulsson, A., Nilsson, A. and Sinkiewicz, G. (2006). Decreased gum bleeding and reduced gingivitis by the probiotic *Lactobacillus reuteri*. *Swed Dental J* 30(2):55-60.

Lipsky, B.A. (1990). Urinary tract infection in men: Epidemiology, pathophysiology, diagnosis and treatment. *Ann Inter Med* 110: 138-150

Lourens-Hattingh, A., Viljoen, B.C. (2002). Survival of probiotic bacteria in South African commercial bio-yogurt. *S Afr J. Sci* 98:298-300.

Mackay A.D., Taylor M.B., Kibbler, C.C. and Hamilton-Miller, J.M.T. *Lactobacillus endocarditis* caused by a probiotic organism. *Clin Infect Dis* 1999; 5:290-292.

Mond, M.C., Gruneberg, R.N. and Smellie, J.M. (1970). A study of childhood urinary tract infection in general practice. *Br Med. J* 1: 602-605.

Nami, Y., Abdullah, N., Haghshenas, B., Radiah, D., Rosli, R. and Khosroushahi, A.Y. (2014). Probiotic potential and biotherapeutic effects of newly isolated vaginal *Lactobacillus acidophilus* 36YL strain on cancer cells. *Anaerobe* 28:29-36.

Näse, L., Hatakka, K., Savilahti, E., Saxelin, M., Ponka, A., Poussa, T., Korpela, R., Meurman, J.H. (2001). Effect of long-term consumption of a probiotic bacterium, *Lactobacillus rhamnosus* GG, in milk on dental caries and caries risk in children. *Caries Res* 35: 412- 420.

Neri, A., Sabha, G. and Samra, Z. (1993).Bacterial vaginosis in pregnancy treated with yogurt. *Acta Obstet Gynaecol Scand* 72:17-19.

Nikawa, H., Makihira, S., Fukushima, H., Nishimura, H., Ozaki, Y., Ishida, K., Darmawan, S., Hamada, T., Hara, K., Matwumoto, A. and Aimi, R. (2004). *Lactobacillus reuteri* in bovine milk fermented decreases the oral carriage of mutans streptococci. *Int J Food Microbiol* 95:219-223.

Nouri, Z., Karami, F., Neyazi, N., Modarressi, M.H., Karimi, R., Khorramizadeh, M.R., Taheri, B., Motevaseli, E. (2016). Dual anti-metastatic and anti-proliferative activity assessment of two probiotics on HeLa and HT-29 cell lines. *Cell J* 18(2):127-34.

O'Hara A.M., O'Regan, P., Fanning, A., O'Mahony, C., Macsharry, J., Lyons, A., Bienenstock, J., O'Manony, L., Shanahan, F. (2006). Functional modulation of human intestinal epithelial cell responses by *Bifidobacterium infantis* and *Lactobacillus salivarius*. *Immunology* 118:202-15.

Paavonen, J., Roberts, P.L., Stevens, C.E., Wolner-Hanssen, P., Brunham, R.C., Hillier, S., Stamm, W.E., Kuo, C.C., DeRoun, T., Holmes, K.K. and Eschenbach, D.A. (1989). Randomized treatment of mucopurulent cervicitis with doxycycline or amoxicillin. 1989. *Am J Obstet Gynecol* 161(1): 128-135.

Pabich, W.L., Fihn, S.D., Stamm, W.E., Scholes, D., Boyko E.J. and Gupta, K. (2003). Prevalence and determinants of vaginal flora alterations in postmenopausal Women. *J Infect. Dis* 188: 1054-1058.

Palmer, C., Bik, E.M., DiGiulio, D.B., Relman, D.A and Brown, P.O. (2007) Development of the human infant intestinal microbiota. *PLoS Biol* 5(7):e177

Rautio, M., Jousimies-Somer, H., Kauma, H., Pietarinen, I., Saxelin, M., Tynkkynen, S. and Koskela, M. (1999). Liver abscess due to a *Lactobacillus rhamnosus* strain indistinguishable from *L. rhamnosus* strain GG. *Clin Infect Dis* 28: 1159-1160.

Reid, G., Bruce, A.W. and Taylor, M. (1995). Instillation of *Lactobacillus* and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. *Microecol Ther* 23:32-45.

Roujeau J, et al. 1995. Medication use and the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. *N. Engl. J. Med.* 333:1600-1606.

Rungsri, P., Akkarachaneeyakorn, N., Wongswanlert, M., Piwat, S., Nantarakchaikul, P. and Teanpaisan, R. (2017). Effect of fermented milk containing *Lactobacillus rhamnosus* SD11 on oral microbiota of healthy volunteers: A randomized clinical trial. *J Dairy Sci* (17): 30756-30567.

Sánchez, A., Rogers, R.J and Sheridan, P. 2004. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. *Int J Dermatol* 43: 709 -715.

Sarjapuram, N., Mekala, N., Singh, M. and Tat, U. (2017). The potential of *Lactobacillus casei* and *Enterococcus faecium* combination as a preventive probiotic against *Entamoeba*. *Probiotics Antimicrob Proteins* 9(2):142-149.

Shalev, E. (2002). Ingestion of probiotics: optional treatment of BV in pregnancy. *IMAJ* 4:357-61-11-13.

Temmerman, R., Pot, B., Huys, G. and Swings, J. (2003). Identification and antibiotic susceptibility of bacterial isolates from probiotic products. *Int J Food Microbiol* 81(1):1-10.

Verhoeven, V., Renard, N., Makar, A., Van Royen, P., Bogers, J.P., Lardon, F., Peeters, M. and Baay, M. 2013. Probiotics enhances the clearance of human papillomavirus-related cervical lesions: a prospective controlled pilot study. *Eur J Cancer Prev* 22: 46-51.

Wolf, B.W., Wheeler, K.B., Ataya, D.G. and Garleb, K.A. (1998) Safety and tolerance of *Lactobacillus reuteri* supplementation to a population infected with the human immunodeficiency virus. *Food Chem Toxicol* 36:1085-1094.

Zivkovic, S.A., Lacomis, D. and Giuliani, M.J. (2001). Sensory neuropathy associated with metronidazole: Report of four cases and review of the literature. *J Clin Neuromuscular Dis* 3 (1)8-12.

